Viking Therapeutics is trading 4.24% up at $42.58 as investors continue reacting to positive VK2735 maintenance-study results released September 22, 2026.
- Patients retained up to 97% of prior weight loss with every-other-week dosing and up to 90% with monthly dosing, supporting broader dosing flexibility.
- The stock remains highly volatile after September 22’s 35.67% surge, while biotech-sector weakness limits gains.